Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.

Cancer. 2013 Aug 15;119(16):3076-83. doi: 10.1002/cncr.28098. Epub 2013 May 14.

2.

Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.

Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SP, Deeley RG, Yang W, Tong Y.

Leukemia. 1996 Jan;10(1):48-55.

PMID:
8558937
3.

Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.

Köhler T, Leiblein S, Borchert S, Eller J, Rost AK, Lassner D, Krahl R, Helbig W, Wagner O, Remke H.

Adv Exp Med Biol. 1999;457:177-85.

PMID:
10500792
4.
6.

The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.

Farawela HM, Khorshied MM, Kassem NM, Kassem HA, Zawam HM.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1323-30. doi: 10.1007/s00432-014-1694-3. Epub 2014 May 8.

PMID:
24804815
7.

Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.

Wuchter C, Karawajew L, Ruppert V, Büchner T, Schoch C, Haferlach T, Ratei R, Dörken B, Ludwig WD.

Leukemia. 1999 Dec;13(12):1943-53.

PMID:
10602414
8.

FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.

Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J.

Haematologica. 2011 May;96(5):681-6. doi: 10.3324/haematol.2010.034074. Epub 2011 Jan 17.

9.

Expression of MRP1 gene in acute leukemia.

Mahjoubi F, Golalipour M, Ghavamzadeh A, Alimoghaddam K.

Sao Paulo Med J. 2008 May 1;126(3):172-9.

10.

Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.

Kim HP, Bernard L, Berkowitz J, Nitta J, Hogge DE.

Cytometry B Clin Cytom. 2012 Sep;82(5):283-94. doi: 10.1002/cyto.b.21028. Epub 2012 May 4.

11.

Assessment of drug resistance in acute myeloid leukemia.

Funato T, Harigae H, Abe S, Sasaki T.

Expert Rev Mol Diagn. 2004 Sep;4(5):705-13. Review.

PMID:
15347263
12.

miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.

Lu F, Zhang J, Ji M, Li P, Du Y, Wang H, Zang S, Ma D, Sun X, Ji C.

Int J Oncol. 2014 Jul;45(1):383-92. doi: 10.3892/ijo.2014.2390. Epub 2014 Apr 16.

PMID:
24756163
13.

MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.

Ho MM, Hogge DE, Ling V.

Exp Hematol. 2008 Apr;36(4):433-42. doi: 10.1016/j.exphem.2007.11.014. Epub 2008 Jan 30.

PMID:
18249061
14.

Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.

Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, Tauscher M, Bullinger L, Krauter J, Heil G, Döhner H, Schlegelberger B, Ganser A.

Haematologica. 2005 Nov;90(11):1484-92.

15.

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL.

Blood. 1999 Aug 1;94(3):1086-99.

16.

An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene.

Guenova ML, Balatzenko GN, Nikolova VR, Spassov BV, Konstantinov SM.

Hematology. 2010 Jun;15(3):135-43. doi: 10.1179/102453309X12583347113690.

PMID:
20557671
17.

Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.

Aref S, Salama O, Al-Tonbary Y, Mansour A.

Hematology. 2004 Apr;9(2):113-21.

PMID:
15203866
18.

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.

Pharmacogenomics. 2015 Jul;16(8):877-90. doi: 10.2217/pgs.15.44. Epub 2015 Jun 17.

19.

ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients.

Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand JY, Marie JP, Jacquet E, Legrand O.

Haematologica. 2011 Sep;96(9):1293-301. doi: 10.3324/haematol.2010.031823. Epub 2011 May 23.

20.

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW, Liu Q.

J Transl Med. 2011 May 19;9:71. doi: 10.1186/1479-5876-9-71.

Supplemental Content

Support Center